 |
 |
 |
 |
 |
 |
 |
|
||||||||||||||||||||
 |
||||||||||||||||||||||
|
VICKY GREGG President and CEO BlueCross BlueShield of Tennessee Vicky Gregg is the president and chief executive officer of Chattanooga-based BlueCross BlueShield of Tennessee--the largest health care provider in the state, with more than $16 billion in claims paid annually. Prior to becoming CEO, Mrs. Gregg occupied several senior leadership positions in the company, including president and chief operating officer, executive vice president, and chief executive officer of Volunteer State Health Plan, the company’s Medicaid HMO. Before joining BCBST, Mrs. Gregg worked for a national, publicly traded health plan where, as market vice president, she oversaw operations, strategic development, acquisition, and health plan service area expansion. A nurse by education, Mrs. Gregg has over 25 years of experience in diverse health care environments including clinical care, hospital administration, long term care, and healthcare benefits and financing. Former Senate Majority Leader Bill Frist (R-TN) appointed Mrs. Gregg to the United States National Institutes of Health Commission on Systemic Interoperability in 2004, which was tasked with developing a strategy for building a nationwide electronic health records network. In 2006, Tennessee Governor Phil Bredesen appointed Mrs. Gregg to the newly-created E-health Advisory Council, a 16-member panel tasked with making recommendations on how to establish an interoperable heath care data exchange in Tennessee. Mrs. Gregg also currently serves on several national boards, including America’s Health Insurance Plans, the BlueCross BlueShield Association, the Council for Affordable Quality Healthcare, the National Institute for Health Care Management Foundation, and the Healthcare Leadership Council. She has received numerous awards and recognitions including Modern Healthcare Top 25 Women in Healthcare, Health Ethics Fellow of the Trust, Vanderbilt School of Nursing Honorary Alumni Award, and Business Tennessee Most Powerful. Mrs. Gregg also serves actively on many community boards including the Electric Power Board of Chattanooga. She is married to Dr. Fred Gregg III, an ophthalmic surgeon, and has two children. ____________________________________
Vice President, Business Development Omnicare Christine Arakelian is currently Vice President of Business Development at Omnicare, the nation’s largest provider of institutional pharmacy services, where she identifies, structures, negotiates and integrates numerous company acquisitions across the United States. Prior to Omnicare, she led corporate development and integration for Neighborcare, previously the second largest provider of institutional pharmacy services in the United States. Prior to Neighborcare, she led business development for Alpharma, a specialty pharmaceutical company, where she identified, structured, negotiated and integrated pharmaceutical co-promotion deals, product acquisitions, in-licensing and product development deals, both in the United States and Europe. Prior to Alpharma, Christine worked in biotechnology business development and structured a variety of development and in-licensing deals. She trained as a corporate and licensing attorney, and has worked both in Europe and the United States. She has a B.A. with honors from the University of Pennsylvania and a J.D. from the University of Virginia. ____________________________________
Co-Head of M&A-Americas Morgan Stanley, Investment Banking Division Michael J. Boublik is a Managing Director in Morgan Stanley’s Mergers and Acquisitions Department, based in New York. Mr. Boublik is Co-Head of the firm's M&A practice in the Americas, and serves on the management committee of the Investment Banking Division. Since joining the firm as an associate in 1989, Mr. Boublik has executed a broad range of financial advisory assignments including buyside, sellside, merger, special committee, restructuring and defense mandates. Mr. Boublik has established a particularly focused area of expertise in the fields of healthcare and technology as well as in general industrial sectors. Over his years at Morgan Stanley, he has executed in excess of 100 transactions, and serves as a senior relationship manager for a variety of the firm’s most notable clients. Mr. Boublik received an MBA in finance from Columbia Business School and an AB in economics from Princeton University. He serves as a member of the Board of Directors of the Children’s Museum of Manhattan. ____________________________________
Co-Founder and General Partner Welsh, Carson, Anderson & Stowe Since 1978 Russell Carson has been a General Partner of Welsh, Carson, Anderson & Stowe (WCAS), one of the Country's largest private investment firms, which he co-founded. Over the past 27 years, WCAS has raised fourteen institutionally funded limited partnerships with total capital in excess of $16 billion and has invested in more than 250 companies. The firm has evolved into the leading specialist in the buyout of privately owned companies in the information services and healthcare industries. Unlike many buyout firms, WCAS emphasizes the growth of acquired businesses and ultimately seeks its financial returns through access to the public stock market. Mr. Carson has focused on WCAS's healthcare investment activities and is currently a director of four portfolio companies. From 1967 to 1978 he was employed by Citicorp Venture Capital subsidiary of Citicorp and served as its Chairman and CEO from 1974 to 1978. Active in community affairs, Mr. Carson is a Trustee of Dartmouth College, Chairman of The Rockefeller University Board of Trustees, Co-Chairman of the Board of Overseers of Columbia Business School, a Trustee of the Metropolitan Museum of Art, a Director of the Partnership for New York City, a Co-Chairman of the New York City Investment Fund, a Director of the World Trade Center Memorial Foundation and Chairman of the Endowment for Inner-City Education. Mr. Carson attended public high school in Toledo, Ohio, prior to receiving a BA degree in economics from Dartmouth College in 1965 and an MBA fro Columbia Business School in 1967. He resides in New York City with his wife Judy and their two children. ____________________________________
Editor-in-Chief Pharmaceutical Executive Patrick Clinton is the editor in chief of Pharmaceutical Executive magazine, the leading industry strategy magazine serving senior executives and operating managers at pharmaceutical and biopharmaceutical companies. Clinton is a magazine editor with more than 30 years experience in consumer and trade publications, including the Chicago Reader, one of the largest and best known of the urban alternative weeklies, Chicago magazine, a 200,000 metropolitan monthly, where he edited business and investigative features, and Men’s Journal. From 1989 to 1997, Clinton was an assistant professor in the Medill School of Journalism at Northwestern University, where he taught writing and editing and served as lead editorial instructor in the school’s Graduate Magazine Publishing Project, a unique cross-disciplinary program in which graduate students create a fully realized start-up magazine. (Two of the student projects Clinton supervised went on to become commercial publications.) From 1998 to 2002, Clinton edited the start-up University Business, hailed by Library Journal as one of the ten best new magazines of the year. Clinton is the author of Guide to Writing for the Business Press, the only current professional text on reporting and writing for trade magazines. He has served as an editorial consultant and trainer for numerous consumer and trade publications. ____________________________________
Co-Head of Healthcare Equity Investment Banking Piper Jaffray Bob DeSutter is a managing director and co-head of the Health Care Team and has 14 years of investment banking experience. DeSutter started the health care advisory practice in 1996 and has transaction experience on numerous buy-side/sell-side, friendly/hostile, strategic/financial buyer and public/private deals. Since 1998, he has advised life sciences clients on sale transactions to Abbott Labs, Astra, Biomet, Boston Scientific, Cardinal Health, Thermo Fisher, Medtronic, Johnson & Johnson, Pfizer, St. Jude, Covidien, Smith & Nephew, GE Medical and Novartis, among others. DeSutter has completed financing transactions involving public and private equity, convertible debt, subordinated debt and senior secured debt. DeSutter is a graduate of the University of Minnesota and the University of Virginia's Darden Graduate School of Business. ____________________________________
Managing Director and Co-Head of Global Healthcare Group Corporate & Investment Banking Banc of America Securities Charles joined Bank of America in 1999 as a managing director responsible for BAS's coverage of healthcare service providers and distributors. He was given responsibility for all of GCIB's healthcare services coverage mid 2003. Charles is one of the most recognized bankers covering healthcare services on Wall Street. Under his direction, BAS has gained the leading market share in the sector in both M&A and financings. Prior to joining the firm, he worked for five years in the Corporate Finance Group at Morgan Stanley primarily focusing on Healthcare. Mr. Ditkoff also worked at Credit Suisse First Boston from 1992 to 1994 as Vice President. Prior to that, he was an Associate at Cravath, Swaine and Moore for five years as a corporate securities lawyer. Charles graduated from Brown University Phi Beta Kappa and magna cum laude with a degree in Political Science and received a J.D. from Yale Law School. ____________________________________ BENJAMIN EDMANDS Managing Director CCMP Capital Advisors, LLC Benjamin Edmands is a Managing Director in the New York office of CCMP Capital. Mr. Edmands focuses on making investments in the healthcare sector and has been responsible for CCMP's investments in CareMore Medical Enterprises, Hanger, DJ Orthopedics, MedQuest Associates and Warner Chilcott. Prior to joining CCMP in 1993, Mr. Edmands worked in Chemical Bank's Investment Banking Group and Structured Finance Group. He holds a B.A. from Colgate University and an M.B.A. from Columbia Business School. Mr. Edmands currently serves on the board of directors of CareMore Medical Enterprises, MedQuest Associates, National Surgical Care and Warner Chilcott. As a premier private equity firm, CCMP Capital Advisors, LLC has invested over $10 billion in over 375 buyout and growth equity transactions since 1984. The foundation of CCMP Capital's investment approach is to leverage the combined strengths of its deep industry expertise and proprietary global network of relationships by focusing on six targeted industries: Healthcare Infrastructure, Consumer, Retail and Services, Energy, Financial Services, Industrials and Media and Telecom. Prior to forming CCMP Capital, the firm's principals led the buyout and growth equity investment business of J.P. Morgan Partners, LLC, a private equity division of JPMorgan Chase & Co. CCMP Capital follows the successful investment strategy its principals developed and implemented as members of JPMorgan Partners. ____________________________________
Partner, Healthcare Transaction Services Leader PricewaterhouseCoopers Steve, a partner, leads the Healthcare Practice in the Transaction Services Group of PricewaterhouseCoopers LLP. He is responsible for delivering a wide range of merger, acquisition, divestiture and corporate finance related services. Steve has over twenty-five years of experience in a wide range of healthcare industry sectors that gives him a broad understanding of the interrelationships amongst the sectors. His sector experience includes health insurance/managed care, general acute-care hospitals, psychiatric hospitals, integrated delivery systems, long-term care, rehabilitation centers, home care, clinical laboratories, medical device manufacturers, and pharmaceutical companies. Steve is an attorney, a Certified Public Accountant, a past President of the Association for Corporate Growth's Philadelphia Chapter and a past Chairman of its Board of Directors. He is a member of the Healthcare Financial Management Association, American Institute of Certified Public Accountants, Pennsylvania Institute of Certified Public Accountants, the Pennsylvania Bar Association and the Philadelphia Bar Association. Steve is a frequent speaker and author on various acquisition, divestiture and financing topics. ____________________________________
Principal Bain Capital Chris Gordon is a Principal at Bain Capital, a leading global private investment firm with more than $65 billion of assets under management. Mr. Gordon joined Bain Capital in 1997. Mr. Gordon has been an important part of the investment team that led transactions in the healthcare, technology, media and communications and consumer industries such as the $33 Billion buyout of Hospital Corporation of America (HCA), the recent acquisition of Quintiles Transnational, Warner Chilcott, Sungard Data Systems, CRC Health, Cumulus Media Partners, Accellent, Burger King, EPOCH Senior Living, and M|C Communications. Prior to joining Bain Capital, Mr. Gordon was a consultant at Bain & Company. Mr. Gordon received an M.B.A. from Harvard Business School, where he was a Baker Scholar and graduated magna cum laude with an A.B. in Economics from Harvard College. Mr. Gordon is a native of Toronto, Canada. ____________________________________ GEORGE HILL Vice President, Investment Banking Leerink Swann George Hill joined the investment banking team at Leerink Swann, LLC in December 2007. Prior to joining the banking team, George had worked as Vice President, Senior Analyst covering Healthcare Technology and Services at Leerink since April 2005. While covering the group at Leerink, the firm had been named "The Best of the Boutiques" in Healthcare Technology research in 2006 and 2007. Prior to joining Leerink Swann, George was a member of the research team at Thomas Weisel Partners covering Healthcare IT and Healthcare Service Companies. Before Weisel, George spent two years as a Research Associate at Citigroup Asset Management. George has a B.A. from Rutgers University. ____________________________________
Partner, Global Head of Healthcare Investment Banking Goldman Sachs Ken is head of the healthcare banking group. He joined Goldman Sachs in 1992 as a member of the Corporate Finance Department. In 1995, Ken joined the healthcare group as a founding member. He became head of Goldman Sachs' global medical device banking practice in 2001. He was named managing director in 2000 and partner in 2002. Prior to joining the firm, Ken was a lieutenant commander and naval aviator in the US Navy. He is a trustee and member of the Board of Meridian Health Systems, Monmouth University and The Rumson Country Day School. Ken earned a BA from University of Colorado and an MBA as a merit fellow at Columbia University Business School. Selected transactions include Pfizer/Warner-Lambert, Warner-Lambert/Agouron, Johnson & Johnson/ Alza, Johnson & Johnson/ Pfizer Consumer, GE/Amersham, GE/Instrumentarium, Medtronic/Minimed, Metronic/Kyphon, Lilly/ICOS. ____________________________________
Managing Director, Corporate Ratings Health Care Team Leader Standard & Poor's Michael J. Kaplan is a Managing Director in Standard & Poor's Industrial Ratings Group and coordinates the activities of the global HealthCare team. Michael has been associated with Standard & Poor's for some 30 years, and since 1983, has specialized in the analysis of companies providing health care services, supplies and equipment, and pharmaceuticals. As the Health Care team leader, he has broad and deep knowledge of health care issues, highlighted by award-winning roles at Standard and Poor's in the development of health care rating criteria and in the publishing arena. He has extensive discussions with leaders in the health care field as a part of the rating process, and shares his perspective on health care developments in a variety of public forums, including electronic and print media. Michael also has ongoing dialogue with Standard & Poor's analysts in health-related rating sectors in the Public and Structured Finance departments, as well as in the Insurance Services area. Michael holds an M.B.A. from New York University's Graduate School of Business and a B.S. from Brooklyn College of the City University of New York. He also is a member of the New York Society of Security Analysts. ____________________________________ KENNETH KLEE Editor Corporate Dealmaker Kenneth Klee leads editorial operations for Corporate Dealmaker, launched by The Deal, LLC in November 2003. Corporate Dealmaker, a bimonthly magazine complemented with a Web site and conferences, helps corporate dealmakers succeed in the deal economy. Klee's previous editorial post was at Newsweek International, where he oversaw the magazine's business section as a senior editor. He wrote on international business topics for Newsweek's domestic and international editions and orchestrated various special sections on international economic and business trends. For much of the 1990's, Klee was the managing editor of Institutional Investor's international editions, responsible for coverage in Europe and Asia. He began his tenure at Institutional Investor in 1987 as a senior editor focused on commercial banking and Wall Street. Klee started his journalism career at Forbes, working on the copy desk. Shortly thereafter, he moved to a technology publication, Datamation, as features editor and later to Venture Magazine as managing editor. Klee earned a bachelors of arts degree in English literature from the University of Wisconsin. ____________________________________
Managing Director Altaris Capital Partners, LLC Mr. Kluger is a founding partner of Altaris. Prior to the formation of Altaris, Mr. Kluger was a founding partner of Liberty Partners where he specialized in healthcare investments. Prior to Liberty Partners, Mr. Kluger held various positions in Merrill Lynch's private equity and investment banking groups. Mr. Kluger received a B.A. in History from Trinity College and an M.B.A. from the University of Chicago, with a concentration in hospital administration. Mr. Kluger is currently a board member of the following Altaris portfolio companies: Brim Healthcare, Classic Industries, Healthcare Waste Solutions, Intermed-Penlon, M2S, Paragon Medical and U.S. HealthWorks. In addition, Mr. Kluger is or has been a member of the board of directors of several publicly traded companies, including Allscripts Healthcare Solutions (NASDAQ), Foundation Health Corporation (NYSE), Monaco Coach Corporation (NYSE) and NFO Research (NYSE). ____________________________________ ROBERT KNOWLES Senior Director, Worldwide Business Development Pfizer, Inc. ____________________________________ JONATHAN C. KORNGOLD Managing Director, Global Head of Healthcare General Atlantic, LLC ____________________________________
Partner Paul Capital Healthcare Mr. Leone joined Paul Capital Partners in 2007 with over 30 years of pharmaceutical industry experience. Most recently, he was President and Chief Executive Officer of Cambrex Corporation, a leading life sciences company. Previously, Mr. Leone was at Aventis, where he served as Senior Vice President and Chief Operating Officer of US Commercial Operations. Among other initiatives, Mr. Leone spearheaded the successful integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst Marion Roussel, to form Aventis. His industry experience also includes both domestic and international management roles with Pfizer and Wyeth. Mr. Leone received his BS degree in Engineering from the US Military Academy at West Point and his MBA from the University of Colorado. ____________________________________ CECILE KOHRS LINDELL Senior Writer The Deal LLC Cecile Kohrs Lindell covers antitrust regulation and related issues for The Deal, LLC. Prior to coming to The Deal in 2006, Lindell worked as a lawyer at the Federal Trade Commission, where she was responsible for sections of the joint FTC/Department of Justice report on competition and regulatory issues surrounding the health care industry, "Improving Health Care: A Dose of Competition." She also spoke about the importance of communication and antitrust law at the Organisation for Economic Co-operation and Development in Paris in February 2006. While attending law school, Lindell was a reporter for BridgeNews, where she also covered antitrust law; reporting and writing about mergers, criminal cartel enforcement and class actions. She also worked in the Washington office of Fried Frank Harris Shriver & Jacobson LLP. After graduating from San Diego State University with a bachelor's of arts degree in journalism, Lindell covered government and the courts at community newspapers in the Washington D.C. region. She received her juris doctorate degree from George Mason University's School of Law. ____________________________________
SVP, Head of Business Development Genmab, Inc. Dr. Annarie Lyles is SVP and Head of Business Development with Genmab, a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. She joined Genmab in 2005 and has nearly two decades of experience in biology-related businesses. Through her prior business development post with Medarex, Inc, she gained a broad knowledge of antibody therapeutics. She has authored several dozen scientific publications, served as Adjunct Associate Professor at Columbia University, and was on the Governing Board of Princeton University's Graduate Alumni Association. Dr. Lyles earned undergraduate and graduate biology degrees from Yale and Princeton Universities. ____________________________________
Associate Director, Business Development Eisai, Inc. June Nguyen serves as Associate Director, Business Development at Eisai, Inc. and is responsible for M&A and Business Development activities in Eisai’s four areas of therapeutic focus – CNS, GI, Oncology and Critical Care. Established in 1995 and ranked among the top–20 U.S. pharmaceutical companies, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with annual sales of approximately $3 billion. Eisai, Inc. is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Among its leading drugs are Aricept® and Aciphex/Pariet® which have realized billion-dollar status globally. Ms. Nguyen has been instrumental in crafting and executing Eisai’s corporate development strategy. Recently, she played a key role in the $3.9 billion acquisition of MGI PHARMA, a biopharmaceutical company focused in oncology and acute care. She has also been involved in Eisai’s acquisition of Morphotek, a biopharmaceutical company focused on the discovery and development of monoclonal antibodies for use in cancer and inflammatory and infectious diseases as well as the acquisition of Ligand Pharmaceuticals oncology-related assets. Moreover, Ms. Nguyen has been instrumental in several business development licensing deals at Eisai. Prior to joining Eisai in 2005, Ms. Nguyen worked as an Equity Research Analyst for Wells Fargo Securities covering Biotechnology. Before that, she worked five years in international M&A for EuroConsult, Inc., a boutique investment bank. Ms. Nguyen holds an M.B.A. in Finance from NYU’s Stern School of Business and a B.S. in Biochemistry and Cell Biology and a B.A. in European History from the University of California, San Diego. She is a member of the Licensing Executives Society and Healthcare Businesswomen’s Association. ____________________________________
Partner Wilson Sonsini Goodrich & Rosati Chul is a partner in the Antitrust Group of Wilson Sonsini Goodrich & Rosati, where he focuses on antitrust counseling, mergers and litigation. He joined the firm in 2007 from the Federal Trade Commission, where he served as the Assistant Director of the Mergers IV Division, heading a 25-lawyer group responsible for mergers in various industries, including hospitals and nursing homes, cable and media, consumer goods, and retailers. Chul's tenure at the FTC was marked by an unsurpassed level of trial experience as trial counsel in nearly every antitrust lawsuit brought by the FTC since 1998. • In the Matter of Evanston Northwestern Healthcare (2005). This was the first successful government challenge of a hospital merger after various government agencies had failed in seven other cases dating back to the 1980s. • In the Matter of Union Oil Company of California (2004). The FTC claimed that an oil company had illegally obtained monopoly power in the technology market for reformulated gasoline by committing fraud against a California regulatory agency, resulting in the potential payment of billions of dollars in royalties by other oil companies. • In the Matter of Chicago Bridge & Iron (2003). The FTC successfully blocked the merger of industrial storage tank manufacturers. The Court of Appeals for the Fifth Circuit recently affirmed the FTC's decision. • FTC v. Libbey (2002). The FTC successfully obtained a preliminary injunction in federal district court to block a merger of glassware manufacturers. • FTC v. Swedish Match (2000). The FTC successfully obtained a preliminary injunction in federal district court to block a merger of chewing tobacco firms. • In the Matter of VISX, Inc. (1999). The FTC claimed that a patent owner had monopolized or attempted to monopolize the technology market for laser-eye surgery by committing fraud and inequitable conduct before the Patent and Trademark Office. EDUCATION: J.D., New York University School of Law; B.A., Swarthmore College ____________________________________
EZRA PERLMAN ____________________________________
Partner Weil, Gotshal & Manges LLP Fiona Schaeffer is a partner at Weil, Gotshal & Manges with expertise in a broad range of antitrust counseling, litigation and transactional matters. She advises leading companies in an array of industries, with particular expertise in the healthcare, financial services and media sectors. She has represented major corporations in complex antitrust litigations, including multi-district treble damages class actions as well as private suits in federal and state courts. She also has expertise in EU competition law and has appeared before the European Courts (ECJ and CFI) and the European Commission and has represented clients in investigations and proceedings in a number of EU member states. She advises private equity and industrial clients on mergers & acquisitions, joint ventures and other combinations and coordinates antitrust approvals for multinational transactions in the US, EU and other jurisdictions worldwide. In an increasingly global economy, her international experience brings added value to clients who conduct business internationally and interact with different legal systems and regulators. Ms. Schaeffer has written and lectured on numerous antitrust subjects in the US and EU. She is a vice chair of the International Antitrust Committee of the ABA's Section of Antitrust Law. She is also a co-chair of the International Antitrust Committee of the ABA's Section of International Law and is a past editor of the Committee's annual Year in Review which comprises a summary of key developments (legislation, conduct and merger cases) in numerous jurisdictions worldwide, published in The International Lawyer. Ms. Schaeffer was recognized in Chambers USA - America's Leading Lawyers for Business 2005, 2006 and 2007 as a leading antitrust lawyer. Ms. Schaeffer is also a member of the Executive Committee of the Antitrust Section of the New York State Bar Association and a past member of the Antitrust & Trade Regulation Committee of the Association of the City Bar of New York in which she also served as liaison to the International Competition Network (ICN). Recent merger cases she has successfully completed include Houghton Mifflin Riverdeep Group plc's acquisition of the Harcourt Education business of Reed Elsevier Group plc and UnitedHealth Group Incorporated's acquisition of PacifiCare Health System. Recent litigations include representing T.H. Lee in a putative nationwide antitrust class action including the leading U.S. private equity firms and representing MasterCard International Incorporated in a multi-district federal and state class action lawsuit (In Re Currency Conversion Fee Antitrust Litigation) and related state actions. ____________________________________ CHARLES SIMMONS Vice President, Corporate Development Bristol Myers Squibb ____________________________________
TODD SISITSKY
Partner Proskauer Rose LLP Richard J. Zall is a Partner at Proskauer Rose LLP and Chair of the Firm's Health Industry practice group. Mr. Zall's practice is focused on corporate and regulatory representation of a wide array of health care clients, including academic medical centers, hospitals, and physician organizations; information technology and medical device companies; managed care and health benefit management companies; and private equity firms. He also advises health care clients and health sector investors on business strategy, product and service development, mergers and acquisitions, and new venture implementation. Mr. Zall provides clients with legal and business counsel in the planning and execution of health care-related corporate transactions, including M&A and equity and debt financings; the structuring of joint ventures and other contractual relationships among various health industry parties; and compliance with federal and state health care regulations. ____________________________________ NATHANIEL M. ZILKHA Principal Kohlberg Kravis Roberts & Co. Nat Zilkha is a Principal at KKR where he focuses on investments in healthcare. Prior to joining KKR, Mr. Zilkha was at Goldman Sachs, where he led the healthcare investing efforts for the Goldman Sachs Capital Partners funds. Over his career he has invested over $1.5 billion of equity in various sectors of healthcare including services, managed care, medical devices and pharmaceuticals. Mr. Zilkha graduated from Princeton University. ____________________________________ The Healthcare Dealmaking Symposium provides a unique opportunity to position yourself and/or your firm as thought leaders in the healthcare, medical device, biotechnology and drug discovery sectors in a face-to-face environment with the corporate and financial executives who will drive the deals in 2008. To be considered for a speaking role, please send your information to: Shamara Ray Manager, Program Development The Healthcare Dealmaking Symposium 770.559.4698 sray@TheDeal.com |
| ||||||||||||||||||||
|
| |
||||||||||||||||||||
|
 |
|
|
                 
      |